TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE
申请人:STEINMETZER Torsten
公开号:US20120225913A1
公开(公告)日:2012-09-06
The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrein, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.
[DE] TRYPSINARTIGE SERINPROTEASE-HEMMSTOFFE, IHRE HERSTELLUNG UND VERWENDUNG<br/>[EN] TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE<br/>[FR] INHIBITEURS DE SÉRINE PROTÉASE DE TYPE TRYPSINE, LEUR FABRICATION ET LEUR UTILISATION
申请人:CURACYTE DISCOVERY GMBH
公开号:WO2008049595A1
公开(公告)日:2008-05-02
[EN] The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive. [FR] L'invention concerne des inhibiteurs des sérine protéases de type trypsine de formule générale (I) qui, outre la plasmine, inhibent également la kallicréine plasmatique, ainsi que leur fabrication et leur utilisation en tant que médicament de préférence pour le traitement des pertes de sang, notamment pour les états hyperfibrinolytiques, lors des transplantations d'organes ou des interventions chirurgicales cardiaques avant tout pour les personnes ayant un pontage cardiopulmonaire, ou en tant que composant d'une colle de fibrine. [DE] Die Erfindung betrifft Hemmstoffe trypsinartiger Serinproleasen der allgemeinen Formel (I) die neben Plasmin auch Plasmakallikrein hemmen, sowie deren Herstellung und Verwendung als Arzneimittel vorzugsweise zur Behandlung von Blutverlust, insbesondere bei hyperfibrinolytischen Zuständen, bei Organtransplantationen oder herzchirurgischen Eingriffen vor allem mit cardiopulmonalem Bypass, oder als Bestandteil eines Fibrinklebers.
Mild and Selective Sodium Azide Mediated Cleavage of <i>p</i>-Nitrobenzoic Esters
作者:José A. Gómez-Vidal、Michael T. Forrester、Richard B. Silverman
DOI:10.1021/ol016104b
日期:2001.8.9
[reaction: see text] A mild and selective cleavage of p-nitrobenzoic esters by sodium azide in methanol is reported. This new methodology is mild enough for use with acid- or base-sensitive compounds. No elimination byproducts are formed. Fmoc- and trifluoroacetyl-amino protecting groups, benzyl esters, and ethyl esters remain unaffected. Less reactive compounds are discussed in terms of steric factors